PDCD1 and neoplasm: To further evaluate the impact of intraperitoneal OBP-702 treatment on intraperitoneal anti-tumor immunity, we analyzed the expression of inhibitory checkpoint molecules such as PD-1 and PD-L1 on immune cells.